Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dactinomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 3/20 | 0.92 |
| ▸ | MAPT | P10636 | 2/20 | 0.92 |
| ▸ | RECQL | P46063 | 2/20 | 0.92 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.92 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.92 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.92 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.92 |
| ▸ | CASP1 | P29466 | 1/20 | 0.92 |
| ▸ | HTT | P42858 | 1/20 | 0.92 |
| ▸ | BLM | P54132 | 1/20 | 0.92 |
| ▸ | CASP7 | P55210 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.92 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.92 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dactinomycin SCHEMBL13659669 | 0.96 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL27304406 | 0.96 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL19770615 | 0.96 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL3844 | 0.96 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL6152 | 0.96 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL26186613 | 0.96 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL6939686 | 0.96 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL3845 | 0.96 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL28168861 | 0.95 | GRB2 (0.99) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL2790145 | 0.95 | GRB2 (0.99) | GRB2MAPTRECQLSMN1; SMN2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310904-B1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS AG (CH) | 2024-04-03 | — | — | EP | claimed |
| US-20200030374-A1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS AG (CH) | 2020-01-30 | — | — | US | claimed |
| US-20190328911-A1 | CELLULAR TARGETED PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL DELIVERY SYSTEM | CELLIS AG (CH) | 2019-10-31 | — | — | US | claimed |
| WO-2019154859-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2019-08-15 | — | — | WO | claimed |
| EP-3475415-A1 | CELLULAR TARGETED PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL DELIVERY SYSTEM | Cellis AG (CH) | 2019-05-01 | — | — | EP | claimed |
| EP-3310904-A1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | Cellis Sp. z.o.o. (Ltd.) (PL) | 2018-04-25 | — | — | EP | claimed |
| WO-2017222398-A1 | CELLULAR TARGETED PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL DELIVERY SYSTEM | CELLIS SP. Z O.O. (PL) | 2017-12-28 | — | — | WO | claimed |
| WO-2016207257-A1 | CELLULAR TARGETED ACTIVE INGREDIENT DELIVERY SYSTEM | CELLIS SP. Z O.O. [LTD.] (PL) | 2016-12-29 | — | — | WO | claimed |
| WO-2016023591-A1 | METHODS AND COMPOSITIONS OF CARRIER SYSTEMS FOR THE PURPOSE OF INTRACELLULAR DRUG TARGETING | HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG (DE) | 2016-02-18 | — | — | WO | claimed |
| WO-2010017827-A1 | 6-SUBSTITUTED 1-SULFONYL-2, 3-DIHYDRO-INDOLE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2010-02-18 | — | — | WO | claimed |
| EP-1717247-A1 | Cyclic peptides binding to the somatostatin receptor | Schering AG (DE) | 2006-11-02 | — | — | EP | claimed |
| EP-1706420-A1 | SITE-SPECIFIC COUPLING OF POLYPEPTIDES | Pharmexa A/S (DK) | 2006-10-04 | — | — | EP | claimed |
| EP-1689365-A1 | DRUG DELIVERY VEHICLES AND USES THEREOF | Pharmexa A/S (DK) | 2006-08-16 | — | — | EP | claimed |
| EP-1689778-A1 | RGD TARGETING MOIETY ITS PORDUCTION AND USE | Pharmexa A/S (DK) | 2006-08-16 | — | — | EP | claimed |
| WO-2005070960-A1 | SITE-SPECIFIC COUPLING OF POLYPEPTIDES | PHARMEXA A/S (DK) | 2005-08-04 | — | — | WO | claimed |
| EP-1557429-A1 | Site-directed coupling of proteins | Vectron Therapeutics AG (DE) | 2005-07-27 | — | — | EP | claimed |
| WO-2005053642-A1 | DRUG DELIVERY VEHICLES AND USES THEREOF | PHARMEXA A/S (DK) | 2005-06-16 | — | — | WO | claimed |
| WO-2005054293-A1 | RGD TARGETING MOIETY ITS PORDUCTION AND USE | PHARMEXA A/S (DK) | 2005-06-16 | — | — | WO | claimed |
| EP-1537858-A1 | Drug delivery vehicles and uses thereof | Vectron Therapeutics AG (DE) | 2005-06-08 | — | — | EP | claimed |
| EP-1538164-A1 | RGD targeting moiety its production and use | Vectron Therapeutics AG (DE) | 2005-06-08 | — | — | EP | claimed |